Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
| Line 35: | Line 35: | ||
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! [[Vildagliptin]]<br/>(Galvus) | ! [[Vildagliptin]]<br/>(Galvus) | ||
| - | ! | + | ! 1792 |
| - | ! | + | ! 78 |
|- | |- | ||
! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
Revision as of 08:56, 13 December 2010
| DPP4 Inhibitor Pharmacokinetics | ||||
|---|---|---|---|---|
| Parameter | Vildagliptin (Galvus) | Sitagliptin (Januvia) | Saxagliptin (Onglyza) | |
| Tmax (hr) | 1.75 | 1-4 | 2 | |
| Cmax (ng/ml) | 290 | 330 | Saxagliptin (Onglyza) | |
| Bioavailability (%) | 85 | 87 | 67 | |
| Protein Binding (%) | 9 | 38 | 0 | |
| T1/2 (hr) | 2-3 | 12.4 | 2.5 | |
| AUC (ng/ml/hr) | Vildagliptin (Galvus) | 1792 | 78 | |
| IC50 (nM) | 3 | 18 | 50 | |
| Renal Clearance (L/h) | 13.0 | 21.0 | 13.8 | |
| Volume Distribution (L) | 71 | 198 | 151 | |
| Dosage (mg) | 100 | 100 | 5 | |
| Metabolism | Hydrolysis | Hepatic (CYP3A4 & CYP2C8) | Hepatic (CYP3A4) | |
For Pharmacokinetic Data References, see: References
